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ABSTRACT 25 
ETHNOPHARMACOLOGICAL RELEVANCE: Shilajit, a herbomineral substance exuded from 26 
rocks in steep mountainous regions, has been used for thousands of years by the Indian Ayurvedic 27 
and Siddha systems of traditional medicine to relieve ailments and enhance quality of life. Although 28 
a large number of therapeutic properties have been ascribed to Shilajit, its therapeutic potential is 29 
still largely unexplored by modern research and many of its claimed bioactivities lack scientific 30 
validation. The present study was undertaken to investigate the antiviral activity of Shilajit against a 31 
panel of viruses including herpes simplex type 1 and 2 (HSV-1, HSV-2), human cytomegalovirus 32 
(HCMV), human respiratory syncytial virus (RSV), human rotavirus (HRV), and vesicular 33 
stomatitis virus (VSV). 34 
MATERIALS AND METHODS: The antiviral activity of Shilajit was assayed in vitro by plaque 35 
reduction and virus yield assays and the major mechanism of action was investigated by virucidal 36 
and time-of-addition assays.  37 
RESULTS: Shilajit exhibited a dose-dependent inhibitory activity against HSV1, HSV2, HCMV, 38 
and RSV infectivity in vitro (EC50 values: 31.08 g/ml, 12.85 g/ml, 34.54 g/ml, and 30.35 g/ml, 39 
respectively), but was inactive against HRV and VSV. Humic acid, a constituent of Shilajit, 40 
displayed the same spectrum of activity. Partial virus inactivation and interference with virus 41 
attachment were both found to contribute to the antiviral activity of Shilajit. 42 
CONCLUSIONS: The results of the present study demonstrate that Shilajit is endowed with broad, 3 
yet specific, antiviral activity in vitro and constitutes a natural source of antiviral substances. 44 
Further work remains to be done to assess its efficacy in vivo.  45 
46 
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1. INTRODUCTION 47 
The global impact of viral infections, the development of antiviral drug resistance, and the 48 
emergence of new viruses are all driving the incessant search for new compounds endowed with 49 
antiviral activity, with the aim of developing novel safe and effective antiviral treatments. 50 
In this context, natural products originating from botanical, animal or mineral sources traditionally 51 
used in ethnomedicine may provide leads for modern antiviral drug development once their 52 
pharmacological potential is verified by scientific investigation.  53 
This paper focuses on Shilajit, a herbomineral substance that has been used for thousands of years 54 
by the Indian Ayurvedic and Siddha systems of traditional medicine to relieve ailments and enhance 55 
the quality of life. It is a blackish-brown matter exuded from rocks in steep mountainous regions, 56 
such as the Himalaya mountains between India and Nepal, as well as mountains in Russia, Tibet, 57 
Afghanistan, and Norway (Agarwal et al., 2007). The chemical characterization of Shilajit has 58 
revealed that it consists of three major components: 1) low and medium molecular weight non-59 
humic organic compounds; 2) medium and high molecular weight DCPs (dibenzo--pyrones-60 
chromoproteins), containing trace metal ions and coloring matter such as carotenoids and indigoids; 61 
and 3) metallo-humates, like  humic acids, fulvic acids and fusims with dibenzo--pyrones in their 62 
core nuclei (Ghosal 2006). Shilajit has been considered a panacea by many traditional systems of 63 
oriental medicine, which have ascribed a vast array of therapeutic properties to this natural 64 
substance (Agarwal et al., 2007, Wilson et al., 2011). Preclinical studies have pointed to the 65 
potential use of Shilajit in various pathological conditions due to its numerous properties/actions, 66 
which include: antiulcerogenic properties, antioxidant properties, complement activator in the 67 
immune system and immunomodulator, antidiabetic properties, anxiolytic and antistress properties, 68 
anti-inflammatory and antiallergic properties, and memory and learning enhancer (Agarwal et al., 69 
2007, Wilson et al., 2011).  However, a recent systematic review of early studies revealed that the 70 
full therapeutic potential of Shilajit is still largely unexplored by modern research and many of its 71 
claimed bioactivities lack scientific validation and remain unproven (Wilson et al., 2011). The 72 
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antiviral potential of Shilajit has yet to be explored, with only its anti-HIV action having received 73 
research attention to date (Ghosal, 2006, Gupta et al., 2010, Rege et al., 2012). The antiviral activity 74 
of one of its components, humic acid has been partially explored (Klöcking et al., 2005). 75 
The present study was undertaken to investigate the antiviral activity of Shilajit against a panel of 6 
viruses, consisting of herpes simplex types 1 and 2 (HSV-1, HSV-2), human cytomegalovirus 77 
(HCMV), human respiratory syncytial virus (RSV), human rotavirus (HRV), and vesicular 78 
stomatitis virus (VSV); these viruses were selected as they encompass a range of viral 79 
characteristics, including the presence or absence of a lipid envelope, different forms of genome 80 
(DNA or RNA), and different tissue/organ tropisms (Collins and Crowe, 2007, Cox and 81 
Christenson, 2012, Landolfo et al., 2003, Roizman et al., 2007). Here, we report on the cytotoxicity, 82 
the antiviral potency, and the probable mechanisms of antiviral action of Shilajit. 83 
84 
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2. MATERIALS AND METHODS. 85 
2.1 Compounds. Shilajit was purchased from Dekha Herbals (Lalitpur, Nepal).  On the basis of the 86 
certificate of analysis provided by the manufacturer, humic acid and fulvic acid represents the 9.5% 87 
and the 26.6 % of Shilajit composition respectively. The following components are also present: 4-88 
methyl catechol, benzoic acid, benzamide, ethyl benzoate, hybdrobenzoin, carboxy ethane, 89 
ammonium benzoate, homocatechol, orcinol,  eudesmol, isodamascol, juniper camphor, and 90 
stearol.   Shilajit was dissolved in bi-distilled sterile water to make a 25mg/ml stock solution prior 91 
to each experiment. Humic acid, heparin, acyclovir and foscarnet were purchased from Sigma (St. 92 
Louis, Mo., USA). 93 
2.2 Cells. African green monkey fibroblastoid kidney cells (Vero, ATCC CCL-81), human 94 
epithelial cells (Hep-2) (ATCC CCL-23), A549 (ATCC CCL-185), and African green monkey 95 
kidney epithelial (MA-104) cells (ATCC CRL-2378.1) were grown as monolayers in Eagle’s 96 
minimal essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with 10% heat 97 
inactivated fetal calf serum (FCS) and 1% antibiotic-anitmycotic solution (Zell Shield, Minerva 98 
Biolabs GmbH, Berlin, Germany).  Low-passage human embryonic lung fibroblasts (HELFs) were 99 
grown as monolayers in Eagle’s minimal essential medium (Gibco-BRL) in the same conditions as 100 
described above with the addition of 1mM sodium pyruvate. 101 
 102 
2.3 Viruses. Clinical isolates of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, 103 
University of Pisa, Italy. HSV-1 and HSV-2 strains were propagated and titrated by plaque assay on 104 
Vero cells. A HSV-2 strain with phenotypic resistance to acyclovir was generated by serial passage 1 5 
in the presence of increasing concentrations of acyclovir, as previously described (Donalisio et al., 106 
2013). HCMV strain Towne was kindly provided by Prof. W. Brune, Heinrich Pette Institut, 107 
Hamburg, Germany; it was propagated and titrated by plaque assay on HELF cells. RSV strain A2 108 
(ATCC VR-1540) was propagated in Hep-2 and titrated by the indirect immunoperoxidase staining 109 
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procedure using an RSV monoclonal antibody (Ab35958; Abcam, Cambridge, United Kingdom), as 110 
described previously (Donalisio et al., 2012). Human rotavirus strain Wa (ATCC VR-2018) was 111 
activated with 5 µg/mL porcine pancreatic trypsin type IX (Sigma, St. Louis, Mo.) for 30 minutes at 112 
37°C and propagated in MA104 cells using MEM containing 0.5  µg trypsin per mL, as described 113 
previously (Graham et al., 2004). Virus stocks were maintained at -80 °C. 114 
 15 
2.4 Cell viability. Cell viability was measured using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-116 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Confluent cell cultures seeded in 17 
96-well plates were incubated with different concentrations of Shilajit or humic acid in triplicate 118 
under the same experimental conditions described for the antiviral assays. Cell viability was 119 
determined using the CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA) according 120 
to the manufacturer’s instructions. Absorbances were measured using a Microplate Reader (Model 121 
680, BIORAD) at 490 nm. The effect on cell viability at different concentrations of the compound 122 
was expressed as a percentage, by comparing absorbances of treated cells with those of cells 123 
incubated with culture medium alone. The 50% cytotoxic concentrations (CC50) and 95% 124 
confidence intervals (CIs) were determined using Prism software (Graph-Pad Software, San Diego, 125 
CA).  126 
2.5 HSV inhibition assays. The effect of Shilajit on HSV infection was evaluated by plaque 127 
reduction assay. Vero cells were pre-plated 24 h in advance in 24-well plates at a density of 10 x 128 
10
4
 cells. Increasing concentrations of compounds were added to cells for 2 h; a mixture of the 129 
compound plus HSV-1, HSV-2, or acyclovir resistant HSV-2 (MOI 0.0003 pfu/cell) was 130 
subsequently added to the cells, which were then incubated at 37 °C for 2 h. The virus inoculum 131 
was then removed and the cells washed and overlaid with a medium containing 1.2% 132 
methylcellulose (Sigma) and serial dilutions of Shilajit or humic acid. After further incubation at 133 
37 °C for 24 h (HSV-2) or 48 h (HSV-1), cells were fixed and stained with 0.1% crystal violet in 134 
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20% ethanol and viral plaques counted. The effective concentration producing 50% reduction in 135 
plaque formation (EC50) was determined using Prism software by comparing drug-treated with 136 
untreated wells. The selectivity index (SI) was calculated by dividing the CC50 by the EC50 value.  137 
2.6 HCMV inhibition assay. HELF cells were pre-plated in a 96-well plate. The following day 138 
serial dilutions of Shilajit or humic acid were added to cells and incubated for 2 h at 37°C. Virus 39 
(MOI 0.005) and compound were then added and the cells incubated for a further 2 h; monolayers 140 
were then washed and overlaid with 1.2% methylcellulose medium supplemented with 3% FCS and 141 
1mM sodium pyruvate. After five days incubation, cells were fixed with cold methanol and acetone 42 
for 1 min and subjected to HCMV-specific immunostaining using an anti-HCMV IEA monoclonal 143 
antibody (11-003; Argene, Verniolle, France). 144 
2.7 RSV inhibition assay. Serial dilutions of the compound were added to A549 cells grown as 145 
monolayers in a 96-well plate and incubated for 2 hours at 37°C. Mixtures of the compounds and 146 
virus (MOI 0.01)  were then added to the cells and incubated for a further 3 hr at 37°C to allow viral 147 
adsorption; the monolayers were then washed and overlaid with 1.2% methylcellulose medium 1 8 
supplemented with Shilajit or humic acid. Three days post-infection, cells were fixed with cold 149 
methanol and acetone for 1 min and subjected to RSV-specific immunostaining. Immunostained 150 
plaques were counted, and the percent inhibition of virus infectivity determined by comparing the 151 
number of plaques in treated wells with the number in untreated control wells.  152 
2.8 Rotavirus inhibition assay. To assess the compound’s ability to inhibit rotavirus infectivity, 153 
assays were carried out using confluent MA104 cell monolayers plated in 96-well trays. Virus 154 
infectivity was activated by adding 5µg porcine trypsin (Sigma)/mL for 30 minutes at 37°C. Cells 155 
were pre-treated for 1 hours with serial dilutions of Shilajit and subsequently activated virus (MOI 156 
0.02 pfu/cell) and Shilajit were added to cells for 1 h at 37°C; cells were then washed and fresh 157 
medium containing Shilajit added. After 16 h, cells were fixed with cold acetone-methanol and viral 158 
titers were determined by indirect immunostaining using the monoclonal antibody mab-0036 159 
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(specific for human 41 kDa inner capsid protein - VP6 - of Rotavirus) purchased from Covalab 160 
(Villeurbanne, France) and the UltraTech HRP Streptavidin-Biotin Detection System (Beckman 161 
Coulter).  162 
2.9 VSV inhibition assay. Vero cells were pre-plated 24 h in advance in 24-well plates at a density 163 
of 10 x 10
4
 cells/well. Increasing concentrations of compound were incubated with cells for 2 h at 64 
37°C, then a mixture of VSV (MOI 0.0005 pfu/cell) and compound added and incubated for a 165 
further 2 h at at 37°C. The virus inoculum was then removed and the cells washed and then overlaid 166 
with a medium containing 1.2% methylcellulose (Sigma) and serial dilutions of Shilajit. After 24 h 67 
of incubation at 37 °C, cells were fixed and stained with 0.1% crystal violet in 20% ethanol and 168 
viral plaques were counted.  169 
 170 
2.10 Time-of-addition assay. Serial dilutions of Shilajit were added to cells: 2 h before infection, 171 
during infection, or post infection. After the incubation time, viral plaques were counted. 172 
 173 
2.11 Investigation of the mechanism of action. Vero and A549 cells were plated as described 174 
above and subjected to 3 different kinds of assay: 175 
2.11.1 Attachment assay. Serial dilutions of Shilajit were mixed with HSV2 or RSV, added 176 
to cooled cells, and incubated for 2 h at 4°C to ensure viral attachment but not entry. After 177 
two gentle washes, cells were overlaid with 1.2% methylcellulose medium and shifted to 178 
37°C for 24 or 72 h. At the end of incubation, plaques were counted. 179 
2.11.2 Entry assay. For entry assays, HSV-2 and RSV at a MOI of 0.001pfu/cell and 0.01 180 
pfu/cell, respectively, were adsorbed for 2 h at 4°C on pre-chilled confluent Vero or A549 181 
cells. Cells were then washed with cold MEM three times to remove unbound virus, treated 182 
with different concentrations of extract, and incubated for 3 h at 37°C. Unpenetrated viruses 183 
were inactivated with acidic glycine for 2 min at room temperature, as previously 184 
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described (Shogan et al., 2006). Cells were then washed with warm medium 3 times and 185 
treated as described above for plaque reduction assay. 186 
2.11.3 Virus inactivation assay. Approximately 10
5
 PFU of HSV2 or 10
4
 PFU of RSV plus 187 
100 g/ml of Shilajit were added to MEM and mixed in a total volume of 100 μl. The virus-188 
compound mixtures were incubated for 2 h at 37 °C or 4°C then diluted serially to the non-89 
inhibitory concentration of test compound; the residual viral infectivity was determined by 190 
viral plaque assay. 91 
 192 
2.12 Virus yield reduction assay. For the virus yield reduction assay, cells were pre-treated with 193 
Shilajit for 2 h at 37°C then infected in duplicate with HSV-2 at an MOI of 0.007 pfu/cell or RSV at 194 
an of MOI 0.005 pfu/cell in presence of Shilajit; following virus adsorption (2 or 3 h at 37°C), the 195 
viral inoculum was removed and cultures were exposed to Shilajit and incubated until control 196 
cultures displayed extensive cytopathology. Supernatants and cells were harvested and cell-free 197 
virus infectivity titers were determined in duplicate by plaque assay in Vero or A549 cell 198 
monolayers. The same experiment was also conducted with Shilajit only being added post-199 
infection. Percent inhibition was determined by comparing the titer measured in the presence of the 200 
compounds to that measured in untreated wells. 201 
 202 
2.13 Data analysis. All results are presented as the mean values from three independent 203 
experiments. The EC50 values for inhibition curves were calculated by regression analysis using the 204 
software GraphPad Prism version 4.0 (GraphPad Software, San Diego, California, U.S.A.) by 205 
fitting a variable slope-sigmoidal dose–response curve.  206 
207 
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3. RESULTS AND DISCUSSION. 208 
To test whether Shilajit can affect HSV-1, HSV-2, HCMV, RSV, human rotavirus, and VSV 209 
infectivity in vitro, we used a complete protection assay in which the compound was added to the 210 
cell culture before, during, and after the infection. Shilajit exhibited dose-dependent inhibitory 211 
activity against HSV1, HSV2, HCMV, and RSV infectivity; the EC50 values are shown in Table 1 212 
in comparison with those of reference antiviral compounds (i.e. acyclovir for HSV, foscarnet for 213 
HCMV, and heparin for RSV). Of note, Shilajit did not affect cell viability at concentrations as high 214 
as 1500 g/mL, demonstrating that the antiviral effect was not a consequence of cytotoxicity. 215 
Although Shilajit proved active against three viruses belonging to the Herpesviridae family (i.e. 216 
HSV-1, HSV-2, and HCMV) and one of the Paramyxoviridae family (RSV), the lack of inhibitory 17 
activity against rotavirus (Reoviridae) and VSV (Rhabdoviridae) indicates that the spectrum of 218 
Shilajit’s activity is specific to definite viruses.  19 
 20 
Table 1. Antiviral activity of Shilajit and of reference compounds 221 
 virus EC50 g/mL*  
(95% C.I.)** 
SI*** 
Shilajit HSV-1 31.08 (23.64-40.87) > 48.26 
 HSV-2  acyclovir sensitive strain 12.85 (6.60-25.02) > 116.7 
 HSV-2 acyclovir resistant strain 14.39 (10.18-20.34) > 104.24 
 HCMV 34.54 (23.96-49.79) > 43.43 
 RSV 30.35 (18.41-50.04) > 49.42 
 Rotavirus - - 
 VSV - - 
Acyclovir HSV-1 0.037 (0.025-0.055) >2702 
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 HSV-2  acyclovir sensitive strain 0.14 (0.098-0.21) >714 
 HSV-2 acyclovir resistant strain 71.84 (41.3-101.4) >1.41 
Foscarnet HCMV 5.17 (3.91-6.93) >24.5 
Heparin RSV 0.048 (0.028-0.082) > 685 
 222 
*   EC50: 50% effective inhibitory concentration  223 
**  95% CI: 95% confidence interval 224 
*** SI: selectivity index 225 
 226 
Moreover, as humic acid is a major component of Shilajit, we tested its antiviral activity. The 7 
results presented in Table 2 demonstrate that humic acid is endowed with antiviral activity against 228 
HSV-1, HSV-2 HCMV, and RSV with EC50 values that are lower than those calculated for Shilajit, 29 
with HCMV as the only exception. These results indicate that humic acid may contribute to the 230 
overall antiviral activity of Shilajit.  231 
 232 
Table 2. Antiviral activity of humic acid 233 
*   EC50: 50% inhibitory concentration  234 
**  95% CI: 95% confidence interval 235 
*** SI: selectivity index 236 
 
virus EC50 g/mL*  
(95% C.I.)** 
SI*** 
Humic Acid HSV-1 4.83 (2.87-8.13) >311 
 HSV-2  acyclovir sensitive strain 2.41 (1.89-3.08) >622 
 HCMV 38.3 (33.8-43.5) 24.6 
 RSV 12.34 (10.41-14.63) >39.2 
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To investigate Shilajit’s mechanism of action we performed a series of time-of-addition assays, in 237 
which the compound was added to the cells only before, or during, or after infection. As shown in 238 
Figure 1, Shilajit exerted dose-dependent inhibitory activity only when added during infection with 239 
EC50 values of 26.74 g/mL for HSV-2, 57.58 g/mL for HSV-1, 41.73 g/ml for HCMV, and 240 
61.44 g/mL for RSV. By contrast, inhibition was limited to the higher doses tested or was absent 241 
altogether in the pre-treatment or post-treatment assays, thus EC50 values could not be determined. 242 
 243 
Fig.1 Time-of-addition assay. Vero (A-B), HELF (C), or A549 (D) cells were treated with Shilajit prior to virus 244 
infection (pre-treatment), during the infection period (during infection), or after infection (post-treatment) with HSV-2 245 
(A), HSV-1 (B), HCMV (C), or  RSV (D). Data are presented as % of control. Values are means ± SEM of three 246 
independent experiments.  247 
 248 
 249 
Results from the time-of-addition assays suggest that Shilajit may either target the early steps of the 250 
virus replicative cycle (i.e. virus attachment or entry into cells) or act as a virucide by irreversibly 251 
inactivating the viral particles. To investigate these hypotheses, HSV-2 and RSV were chosen for 252 
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further experiments as representative viruses of the Herpesviridae and Paramyxoviridae virus 253 
families, respectively. First, we carried out an attachment assay, an experimental condition in which 254 
the virus is allowed to bind to the surface of the host cells, in the presence or absence of Shilajit, but 255 
not undergo cell entry. As shown in Fig. 2A, Shilajit inhibited HSV-2 and RSV infectivity with 256 
EC50 of 14.20 g/ml and 25.70 g/ml, respectively; values that are comparable to those reported in 257 
Table 1. This result indicates that the antiviral activity of Shilajit depends, at least in part, on its 258 
capacity to prevent the attachment of the viruses to the cell surface. By contrast, when the antiviral 259 
activity of Shilajit was tested using an entry assay in which Shilajit was added immediately after 260 
virus attachment to assess its ability to prevent entry, only a weak inhibition was observed at high 261 
doses (Fig. 2B). 62 
 263 
Fig.2 Attachment and entry assay. In the attachment assay (A), Vero cells were infected with HSV-2 and A549 cells 264 
were infected with RSV in presence of serial dilutions of Shilajit; inoculated cultures were then kept for 2 h at 4°C to 265 
allow virus attachment but not entry, and then tested in plaque reduction assays. In the entry assay (B), cells were 266 
infected in the absence of Shilajit and once again kept at 4°C for 2 h to allow virus attachment; serial dilutions of the 267 
compound were added to washed cells and the temperature then shifted to 37°C to allow entry. After a single wash with 268 
acidic glycine to remove virus particles from the cell surface, cells were overlaid with medium containing 269 
methylcellulose. Data are presented as % infectivity of control. Values are mean ± SEM of three separate 270 
determinations.  271 
 272 
To explore the possibility that Shilajit also exerts direct virus-inactivating activity, a virucidal assay 273 
was performed using the effective concentration that reduced virus infection almost completely 274 
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(EC90) in the standard assay. To this end, HSV-2 and RSV aliquots were incubated with 100 g/ml 275 
Shilajit at 4°C or 37°C for 2 h. After incubation, the samples were titrated on Vero or A549 cells 276 
using high dilutions at which Shilajit was no longer active as an antiviral. When the incubations 277 
were carried out at 37°C, Shilajit produced a significant loss of both HSV-2 (71.2% inhibition) and 278 
RSV (74.4% inhibition) titers, although the treatment did not completely abrogate infectivity. This 279 
result indicates that partial virus inactivation contributes to the overall antiviral activity of Shilajit. 280 
By contrast, no virucidal activity was observed when the incubation was carried out at 4°C. This 281 
latter result rules out the possibility that the antiviral activity observed in the attachment assay, 282 
performed at 4°C, was due to a direct virus inactivation.  283 
Some preliminary conclusions can be drawn on the main mode of antiviral action of Shilajit. Time-84 
of-addition and virucidal assays indicate that the inhibitory effect mainly depends on the capacity of 285 
Shilajit to interact with the virus particles, rather than with cell components, thereby preventing 86 
virus attachment to the cell surface. This view is supported by several lines of evidence. First, cells 287 
pre-treated with Shilajit remained fully susceptible to virus infection, thus excluding the possibility 288 
that this compound could act by stably interacting with a cellular component(s) and thereby prevent 289 
its(their) interaction with viral glycoproteins. Second, the results of attachment and entry assays 290 
demonstrate that Shilajit blocks the adsorption of HSV-2 and RSV virions to the cell surface, but 2 1 
not entry. Third, pre-incubation of HSV-2 and RSV virions with Shilajit resulted in loss of 292 
infectivity, suggesting that both partial virus inactivation and interference with virus attachment 293 
contribute to the antiviral activity.  294 
 295 
To complete the in vitro analysis of the antiviral potential of Shilajit against HSV-2 and RSV, the 296 
compound was also evaluated by viral yield reduction assay – a more stringent test which allows 297 
multiple cycles of viral replication to occur before measuring the production of infectious viruses. 298 
The assay was conducted under two different conditions: 1) Shilajit was added before, during, and 299 
after infection (Fig 3 A-C); and 2) only after infection (Fig 3 B-D). In both cases, Shilajit was 300 
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active, with the strongest inhibition occurring in the first condition. This result indicates that besides 301 
preventing initial viral infection, Shilajit can also limit ongoing infection in vitro. This feature 302 
might be relevant for in vivo infections, characterized by the continuous release of virions by 303 
infected cells that promptly interact with neighboring cells, often resulting in direct cell-to-cell 304 
spread and syncytia formation. Of note, an acyclovir-resistant HSV-2 strain was as susceptible to 305 
Shilajit as the acyclovir-sensitive strain (Table 1), suggesting that the mode of antiviral action is 306 
different from that of acyclovir - a widely used inhibitor of the viral DNA polymerase. This latter 307 
feature, along with Shilajit's low cytotoxicity and favorable selectivity index make this natural 308 
compound a promising starting material for bioguided fractionation, with the aim of identifying 309 
anti-HSV-2 or anti-RSV compounds with novel mechanisms of action, which might also be used 310 
against acyclovir-resistant HSV-2 strains.  311 
Overall, the results of the present study demonstrate that Shilajit constitutes a natural source of 312 
antiviral substances endowed with broad, yet specific, antiviral activity in vitro and are in line with 313 
the use of Shilajit as antiseptic and germicide in traditional medicine (Wilson et al., 2011). In this 314 
work, we demonstrated that humic acid, a major component of Shilajit, is endowed with antiviral 15 
activity, however, further work remains to be done to isolate the active constituents and elucidate 316 
their mechanism(s) of action. 17 
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Fig. 3 Viral yield reduction. Panels A and B refer to Vero cells infected with HSV-2; while panels C and D refer to 319 
Hep-2 cells infected with RSV. Shilajit was added before, during, and after infection (A, C), or only after infection (B, 320 
D). When the cytopathic effect involved the whole monolayer of untreated cells, the supernatant was harvested and 321 
titrated. Plaques were counted and percent infection calculated by comparing treated with untreated (control) wells. 322 
Viral titers (expressed as PFU/ml) are shown as means plus SEM for three independent 323 
experiments. *, P<0.05. 324 
325 
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FIGURE CAPTIONS 386 
 387 
Fig.1 Time-of-addition assay. Vero (A-B), HELF (C), or A549 (D) cells were treated with Shilajit 388 
prior to virus infection (pre-treatment), during the infection period (during infection), or after 389 
infection (post-treatment) with HSV-2 (A), HSV-1 (B), HCMV (C), or  RSV (D). Data are 390 
presented as % of control. Values are means ± SEM of three independent experiments.  391 
 392 
Fig.2 Attachment and entry assay. In the attachment assay (A), Vero cells were infected with 393 
HSV-2 and A549 cells were infected with RSV in presence of serial dilutions of Shilajit; inoculated 394 
cultures were then kept for 2 h at 4°C to allow virus attachment but not entry, and then tested in 395 
plaque reduction assays. In the entry assay (B), cells were infected in the absence of Shilajit and 396 
once again kept at 4°C for 2 h to allow virus attachment; serial dilutions of the compound were 397 
added to washed cells and the temperature then shifted to 37°C to allow entry. After a single wash 3 8 
with acidic glycine to remove virus particles from the cell surface, cells were overlaid with medium 399 
containing methylcellulose. Data are presented as % infectivity of control. Values are mean ± SEM 400 
of three separate determinations.  401 
 402 
Fig. 3 Viral yield reduction. Panels A and B refer to Vero cells infected with HSV-2; while panels 403 
C and D refer to Hep-2 cells infected with RSV. Shilajit was added before, during, and after 04 
infection (A, C), or only after infection (B, D). When the cytopathic effect involved the whole 405 
monolayer of untreated cells, the supernatant was harvested and titrated. Plaques were counted and 406 
percent infection calculated by comparing treated with untreated (control) wells. Viral titers 407 
(expressed as PFU/ml) are shown as means plus SEM for three independent experiments. *, P<0.05. 408 
Table 1. Antiviral activity of Shilajit and of reference compounds 
 virus EC50 g/mL*  
(95% C.I.)** 
SI*** 
Shilajit HSV-1 31.08 (23.64-40.87) > 48.26 
 HSV-2  acyclovir sensitive strain 12.85 (6.60-25.02) > 116.7 
 HSV-2 acyclovir resistant strain 14.39 (10.18-20.34) > 104.24 
 HCMV 34.54 (23.96-49.79) > 43.43 
 RSV 30.35 (18.41-50.04) > 49.42 
 Rotavirus - - 
 VSV - - 
Acyclovir HSV-1 0.037 (0.025-0.055) >2702 
 HSV-2  acyclovir sensitive strain 0.14 (0.098-0.21) >714 
 HSV-2 acyclovir resistant strain 71.84 (41.3-101.4) >1.41 
Foscarnet HCMV 5.17 (3.91-6.93) >24.5 
Heparin RSV 0.048 (0.028-0.082) > 685 
 
*   EC50: 50% effective inhibitory concentration  
**  95% CI: 95% confidence interval 
*** SI: selectivity index 
 
Table 1
Table 2. Antiviral activity of humic acid 
 
*   EC50: 50% inhibitory concentration  
**  95% CI: 95% confidence interval 
*** SI: selectivity index 
 
 
virus EC50 g/mL*  
(95% C.I.)** 
SI*** 
Humic Acid HSV-1 4.83 (2.87-8.13) >311 
 HSV-2  acyclovir sensitive strain 2.41 (1.89-3.08) >622 
 HCMV 38.3 (33.8-43.5) 24.6 
 RSV 12.34 (10.41-14.63) >39.2 
Table 2
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